{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:01:38Z","timestamp":1790276498186,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":1221,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":42,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Patients with tumor-induced osteomalacia (TIO), an acquired paraneoplastic condition characterized by osteomalacia due to hypophosphatemia, exhibit a similar clinical picture to those with X-linked hypophosphatemic rickets\/osteomalacia (XLH). The human monoclonal anti-fibroblast growth factor 23 (FGF23) antibody burosumab (KRN23) increases serum phosphate and improves bone turnover, fracture healing, pain, and physical function in XLH patients by inhibiting circulating FGF23; thus, burosumab is expected to be an effective treatment for TIO. We report here an interim analysis of a multicenter, open-label, intraindividual dose-adjustment study of burosumab (0.3 to 2.0\u2009mg\/kg every 4\u2009weeks) in Japanese and Korean TIO patients. The primary endpoint was the fasting serum phosphate level at each visit. Key secondary endpoints were changes over time in bone biomarkers, pharmacodynamic markers, bone histomorphometric parameters, motor function, and patient-reported outcomes. Safety was assessed based on treatment-emergent adverse events (TEAEs). Thirteen patients received burosumab treatment, of whom 4 underwent bone biopsy. The mean dose after week 112 was approximately 1.0\u2009mg\/kg. After the first burosumab administration, mean serum phosphate levels increased and remained above the lower limit of normal and in the normal range from weeks 14 to 112. Bone biomarkers initially increased, reaching maximum values at week 16 or 24, and then gradually decreased. After burosumab treatment, patients were able to walk further (evaluated by the 6-minute walk test), reported decreased pain levels, and showed a tendency toward healing of baseline fractures and pseudofractures. Two patients discontinued, one each due to disease progression and consent withdrawal. Burosumab was generally well tolerated, with no treatment-related TEAEs of grade \u22653 and no treatment-related serious AEs. In conclusion, the interim results of this first study of burosumab to treat TIO patients indicate that this drug has the potential to provide clinical benefit for patients with unresectable tumors. The full study results are eagerly anticipated. \u00a9 2020 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR)..<\/jats:p>","DOI":"10.1002\/jbmr.4184","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T17:29:48Z","timestamp":1600882188000},"page":"262-270","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9077-2631","authenticated-orcid":false,"given":"Yasuo","family":"Imanishi","sequence":"first","affiliation":[{"name":"Department of Metabolism, Endocrinology, and Molecular Medicine Osaka City University Graduate School of Medicine Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology The University of Tokyo Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-5638","authenticated-orcid":false,"given":"Yumie","family":"Rhee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Severance Hospital, Endocrine Research Institute Yonsei University College of Medicine Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Okinaka Memorial Institute for Medical Research Tokyo Japan"},{"name":"Endocrine Center Toranomon Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Soo","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University Hospital Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology Kobe University Hospital Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Onuma","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kojima","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kanematsu","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Kanda","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Seino","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Osaka Hospital, Japan Community Healthcare Organization (JCHO) Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences Tokushima University Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"issue":"11","key":"2024012713523550100_jbmr4184-bib-0001","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024012713523550100_jbmr4184-bib-0002","doi-asserted-by":"crossref","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","article-title":"Tumour-induced osteomalacia","volume":"3","author":"Minisola","year":"2017","journal-title":"Nat Rev Dis Primers."},{"issue":"8","key":"2024012713523550100_jbmr4184-bib-0003","doi-asserted-by":"crossref","first-page":"e10190","DOI":"10.1002\/jbm4.10190","article-title":"FGF23, hypophosphatemia, and emerging treatments","volume":"3","author":"Imel","year":"2019","journal-title":"JBMR Plus."},{"key":"2024012713523550100_jbmr4184-bib-0004","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bonr.2017.09.002","article-title":"Tumor-induced osteomalacia","volume":"7","author":"Florenzano","year":"2017","journal-title":"Bone Rep."},{"issue":"3","key":"2024012713523550100_jbmr4184-bib-0005","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1210\/er.2017-00220","article-title":"X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases: prospect for new treatment","volume":"39","author":"Kinoshita","year":"2018","journal-title":"Endocr Rev."},{"issue":"2","key":"2024012713523550100_jbmr4184-bib-0006","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11914-015-0259-y","article-title":"Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis","volume":"13","author":"Goldsweig","year":"2015","journal-title":"Curr Osteoporos Rep."},{"issue":"3","key":"2024012713523550100_jbmr4184-bib-0007","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1530\/ERC-11-0006","article-title":"Tumor-induced osteomalacia","volume":"18","author":"Chong","year":"2011","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"2024012713523550100_jbmr4184-bib-0008","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00223-009-9216-z","article-title":"Effects of tumor-induced osteomalacia on the bone mineralization process","volume":"84","author":"Nawrot-Wawrzyniak","year":"2009","journal-title":"Calcif Tissue Int."},{"key":"2024012713523550100_jbmr4184-bib-0009","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bonr.2018.03.005","article-title":"Bone histomorphometry in the evaluation of osteomalacia","volume":"8","author":"Bhan","year":"2018","journal-title":"Bone Rep."},{"issue":"7","key":"2024012713523550100_jbmr4184-bib-0010","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s00198-017-4007-2","article-title":"Tumor-induced osteomalacia: experience from a South American academic center","volume":"28","author":"Gonz\u00e1lez","year":"2017","journal-title":"Osteoporos Int."},{"issue":"6","key":"2024012713523550100_jbmr4184-bib-0011","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11926-015-0512-5","article-title":"Tumor-induced osteomalacia: an up-to-date review","volume":"17","author":"Hautmann","year":"2015","journal-title":"Curr Rheumatol Rep."},{"issue":"6","key":"2024012713523550100_jbmr4184-bib-0012","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jbmr.1881","article-title":"Tumor localization and biochemical response to cure in tumor-induced osteomalacia","volume":"28","author":"Chong","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2024012713523550100_jbmr4184-bib-0013","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","article-title":"Burosumab: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs."},{"issue":"7","key":"2024012713523550100_jbmr4184-bib-0014","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2024012713523550100_jbmr4184-bib-0015","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"12","key":"2024012713523550100_jbmr4184-bib-0016","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J Bone Miner Res."},{"key":"2024012713523550100_jbmr4184-bib-0017","author":"Kyowa Kirin, Inc","year":"2020"},{"key":"2024012713523550100_jbmr4184-bib-0018","author":"Kyowa Kirin Holdings B.V","year":"2020"},{"key":"2024012713523550100_jbmr4184-bib-0019","author":"Kyowa Kirin Co., Ltd"},{"key":"2024012713523550100_jbmr4184-bib-0020","author":"Carpenter","year":"2016"},{"issue":"1","key":"2024012713523550100_jbmr4184-bib-0021","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jbspin.2019.07.012","article-title":"Burosumab in tumor-induced osteomalacia: a case report","volume":"87","author":"Day","year":"2020","journal-title":"Joint Bone Spine."},{"issue":"6","key":"2024012713523550100_jbmr4184-bib-0022","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"2024012713523550100_jbmr4184-bib-0023","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4248\/BR201302002","article-title":"FGF23 and phosphate wasting disorders","volume":"1","author":"Huang","year":"2013","journal-title":"Bone Res."},{"issue":"9","key":"2024012713523550100_jbmr4184-bib-0024","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr J."},{"issue":"2","key":"2024012713523550100_jbmr4184-bib-0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12020-011-9512-z","article-title":"Evaluation of bone markers in hypophosphatemic rickets\/osteomalacia","volume":"40","author":"Nagata","year":"2011","journal-title":"Endocrine."},{"issue":"3","key":"2024012713523550100_jbmr4184-bib-0026","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int."},{"key":"2024012713523550100_jbmr4184-bib-0027","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00774-015-0698-7","article-title":"Pathogenesis and diagnostic criteria for rickets and osteomalacia\u2014proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society","volume":"33","author":"Fukumoto","year":"2015","journal-title":"J Bone Miner Metab."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4184","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4184","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/2\/262\/55457530\/jbmr4184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/2\/262\/55457530\/jbmr4184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:06:07Z","timestamp":1710327967000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/36\/2\/262-270\/7516669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,9,23]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4184","relation":{"has-review":[{"id-type":"doi","id":"10.1002\/JBMR.4184\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4184\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4184\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4184\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4184\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4184\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4184\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4184\/v1\/review2","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"2020-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}